Yuhan Corporation – Product Pipeline Review

Global Markets Direct’s, ‘Yuhan Corporation – Product Pipeline Review – 2016’, provides an overview of the Yuhan Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Yuhan Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Yuhan Corporation

The report provides overview of Yuhan Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Yuhan Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Yuhan Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Yuhan Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Yuhan Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Yuhan Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Yuhan Corporation Snapshot 6

Yuhan Corporation Overview 6

Key Information 6

Key Facts 6

Yuhan Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

Yuhan Corporation - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Yuhan Corporation - Pipeline Products Glance 15

Yuhan Corporation - Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Yuhan Corporation - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Yuhan Corporation - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Yuhan Corporation - Drug Profiles 19

(metformin hydrochloride SR + rosuvastatin calcium) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

bilastine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

YH-12852 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

YH-14618 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

(amlodipine maleate + chlorthalidone + telmisartan) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

YH-22189 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

YH-1177 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

YH-14619 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

YH-18406 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

YH-18420 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

YH-24931 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

YH-25348 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

YH-25448 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

YH-25723 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

YH-BIO 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

YH-GKA 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

YH-NCE2 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

YH-NCE3 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

YH-NCE4 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

YH-siRNA1 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

YH-siRNA2 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

YH-siRNA3 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Yuhan Corporation - Pipeline Analysis 43

Yuhan Corporation - Pipeline Products by Target 43

Yuhan Corporation - Pipeline Products by Route of Administration 45

Yuhan Corporation - Pipeline Products by Molecule Type 46

Yuhan Corporation - Pipeline Products by Mechanism of Action 47

Yuhan Corporation - Recent Pipeline Updates 48

Yuhan Corporation - Dormant Projects 49

Yuhan Corporation - Company Statement 50

Yuhan Corporation - Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Yuhan Corporation - Key Manufacturing Facilities 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Yuhan Corporation, Key Information 6

Yuhan Corporation, Key Facts 6

Yuhan Corporation – Pipeline by Indication, 2016 8

Yuhan Corporation – Pipeline by Stage of Development, 2016 10

Yuhan Corporation – Monotherapy Products in Pipeline, 2016 11

Yuhan Corporation – Combination Treatment Modalities in Pipeline, 2016 12

Yuhan Corporation – Partnered Products in Pipeline, 2016 13

Yuhan Corporation – Partnered Products/ Combination Treatment Modalities, 2016 14

Yuhan Corporation – Phase III, 2016 15

Yuhan Corporation – Phase II, 2016 16

Yuhan Corporation – Phase I, 2016 17

Yuhan Corporation – Preclinical, 2016 18

Yuhan Corporation – Pipeline by Target, 2016 44

Yuhan Corporation – Pipeline by Route of Administration, 2016 45

Yuhan Corporation – Pipeline by Molecule Type, 2016 46

Yuhan Corporation – Pipeline Products by Mechanism of Action, 2016 47

Yuhan Corporation – Recent Pipeline Updates, 2016 48

Yuhan Corporation – Dormant Developmental Projects,2016 49

Yuhan Corporation, Other Locations 51

Yuhan Corporation, Subsidiaries 51

Yuhan Corporation, Key Manufacturing Facilities 52

List of Figures

List of Figures

Yuhan Corporation – Pipeline by Top 10 Indication, 2016 8

Yuhan Corporation – Pipeline by Stage of Development, 2016 10

Yuhan Corporation – Monotherapy Products in Pipeline, 2016 11

Yuhan Corporation – Combination Treatment Modalities in Pipeline, 2016 12

Yuhan Corporation – Partnered Products in Pipeline, 2016 13

Yuhan Corporation – Pipeline by Top 10 Target, 2016 43

Yuhan Corporation – Pipeline by Route of Administration, 2016 45

Yuhan Corporation – Pipeline by Molecule Type, 2016 46

Yuhan Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 47

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared